NCT05503966

Combining Antidepressants and Attention Bias Modification in Depression

Combining Antidepressants and Attention Bias Modification in Depression: A Randomized Controlled Trial in Primary Care
University of Oslo·ClinicalTrials.gov·behavioralRecruiting
View on ClinicalTrials.gov
Study focus
Disease/Condition
Depressive Disorder
Drug/Device/Intervention
Attentional Bias Modification
Study type
Interventional
Intervention type
behavioral
Sponsor & location
Primary sponsor
University of Oslo
Location
Oslo, Norway
Timeline & enrollment
Phase
N/A
Start date
Sep 22, 2022
End date
Dec 30, 2024
Enrollment
246 participants
Primary outcome

Hamilton Depression Rating Scale,Beck Depression Inventory II

Summary

Background: Major depressive disorder (MDD) is a highly prevalent psychiatric condition
 associated with significant disability, mortality and economic burden. A large proportion of
 MDD patients are treated in primary health care (PHC) in the municipalities and represent a
 challenging group. Attentional Bias Modification (ABM) training in combination with
 antidepressants (SSRIs) could be an effective treatment. The overall aim of this study is to
 test the hypothesis that adding an ABM procedure to regular treatment with antidepressants in
 PHC will result in further improvement of symptoms compared to treatment with antidepressants
 alone (treatment as usual, TAU) and as compared to an active comparison condition.
 
 Methods: A total of 246 patients with a diagnosis of MDD will be included in this study. The
 study is a three-armed pragmatic randomized controlled trial comparing the efficacy of ABM as
 add-on to treatment with antidepressants in primary care (ABM condition) compared to standard
 antidepressant treatment (TAU condition). In a third group participants will complete the
 same schedule of intermediate assessments as the ABM condition in addition to TAU , but no
 ABM, thus controlling for the non-training-specific aspects of the ABM condition (SSRI Active
 comparison group).
 
 Discussion:
 
 The clinical outcome of this study may help develop easy accessible, low cost treatment of
 depression in PHC. Moreover, the study aims to broaden our knowledge of optimal treatment for
 patients with a MDD by providing adjunct treatment to facilitate recovery and long term gain

ICD-10 classifications
Depressive conduct disorderRecurrent depressive disorder, unspecifiedRecurrent depressive disorderOther recurrent depressive disordersRecurrent depressive disorder, currently in remission
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05503966
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05503966 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Oslo and is currently Recruiting. The study focuses on Depressive Disorder. Target enrollment is 246 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.